



Drug Name: Mavyret, Vosevi

Effective Date: 7/1/2018

Last Revision Date: 07-2018

Review Date: 07-2018, 12-2019, 09-2020

Drug Name: Mavyret and Vosevi	
Prescriber Restrictions:	For coverage under Medicaid: Patients with Stage 0, 1, or 2 disease: Prescriber restriction would <u>NOT</u> apply - The requesting prescriber does <u>NOT</u> have to be registered with the State of RI EOHHS with Preferred Provider Status. Patients with Stage 3 or 4 disease: The requesting prescriber must be registered with the State of RI EOHHS with Preferred Provider Status.
Required Medical Information:	• Patient is being treated for chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5 or 6; and • Patient has a positive quantitative viral load with test date within 90 days of PA request; and • Patient's stage of hepatic disease has been provided (All patients with documented CHC Stages 0 to 4 are eligible for treatment); and • Documentation of test used to determine disease stage must be provided (ie. APRI score, Fibroscan score, Fibrotest score, Imaging study consistent with cirrhosis, Liver biopsy indicating METAVIR score); and • Presence or absence of cirrhosis (compensated or decompensated if cirrhotic) and for a patient with decompensated hepatic function, the patient is under the care of a specialist (e.g. liver transplant center); and • Patient's CHC treatment status is provided (e.g. treatment naïve or treatment experienced) along with previous CHC therapy (if relevant).
Coverage Duration:	Up to a total of 84 days of therapy from date of approval • If the member is continuing treatment, the request will be authorized until the appropriate treatment duration is completed.